永赢中证全指医疗器械ETF发起联接C(013416)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
-7,625,885.61 |
-57,547,675.81 |
-17,822,503.74 |
-7,277,385.82 |
| 本期利润 |
-2,756,648.28 |
-33,499,446.30 |
-42,597,623.76 |
-25,707,861.80 |
| 加权平均基金份额本期利润 |
-0.01 |
-0.09 |
-0.11 |
-0.09 |
| 本期加权平均净值利润率(%) |
-1.36 |
-14.40 |
-17.52 |
-12.17 |
| 本期基金份额净值增长率(%) |
-1.24 |
-13.94 |
-15.98 |
-12.27 |
| 期末可供分配利润 |
-133,400,737.93 |
-132,315,928.11 |
-152,221,806.19 |
-108,985,186.53 |
| 期末可供分配基金份额利润 |
-0.40 |
-0.39 |
-0.40 |
-0.29 |
| 期末基金资产净值 |
203,694,102.83 |
208,621,798.96 |
225,828,660.48 |
268,100,587.84 |
| 期末基金份额净值 |
0.60 |
0.61 |
0.60 |
0.71 |
| 基金份额累计净值增长率(%) |
-39.57 |
-38.81 |
-40.26 |
-28.90 |
微信公众号
证券之星APP
基本资料
